Literature DB >> 27567135

Myocardial Native T1 Time in Patients With Hypertrophic Cardiomyopathy.

Shingo Kato1, Shiro Nakamori2, Steven Bellm2, Jihye Jang2, Tamer Basha2, Martin Maron3, Warren J Manning4, Reza Nezafat5.   

Abstract

In hypertrophic cardiomyopathy (HC), there are significant variations in left ventricular (LV) wall thickness and fibrosis, which necessitates a volumetric coverage. Slice-interleaved T1 (STONE) mapping sequence allows for the assessment of native T1 time with complete coverage of LV myocardium. The aims of this study were to evaluate spatial heterogeneity of native T1 time in patients with HC. Twenty-nine patients with HC (55 ± 16 years) and 15 healthy adult control subjects (46 ± 19 years) were studied. Native T1 mapping was performed using STONE sequence which enables acquisition of 5 slices in the short-axis plane within a 90 seconds free-breathing scan. We measured LV native T1 time and maximum LV wall thickness in each 16 segments from 3 slices (basal, midventricular and apical slice). Late gadolinium enhanced (LGE) magnetic resonance imaging was acquired to assess the presence of myocardial enhancement. In patients with HC, LV native T1 time was significantly elevated compared with healthy controls, regardless of the presence or absence of LGE (mean native T1 time; LGE positive segments from HC, 1,141 ± 46 ms; LGE negative segments from HC, 1,114 ± 56 ms; segments from healthy controls, 1,065 ± 35 ms, p <0.001). Elevation of native T1 time was defined as >1,135 ms, which was +2SD of native T1 time by STONE sequence in healthy controls. A total of 120 of 405 (30%) LGE negative segments from patients with HC showed elevated native T1 time. Prevalence of segments with elevated native T1 time for basal, midventricular, and apical slice was 29%, 25%, 38%, respectively. Significant correlation was found between LV wall thickness and LV native T1 time (y = 0.029 × -22.6, p <0.001 by Spearman's correlation coefficient). In conclusion, substantial number of segments without LGE showed elevation of native T1 time, and whole-heart T1 mapping revealed heterogeneity of myocardial native T1 time in patients with HC.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27567135      PMCID: PMC5599251          DOI: 10.1016/j.amjcard.2016.07.010

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  28 in total

1.  Free-breathing multislice native myocardial T1 mapping using the slice-interleaved T1 (STONE) sequence.

Authors:  Sebastian Weingärtner; Sébastien Roujol; Mehmet Akçakaya; Tamer A Basha; Reza Nezafat
Journal:  Magn Reson Med       Date:  2014-08-01       Impact factor: 4.668

2.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

3.  Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy.

Authors:  Oliver Bruder; Anja Wagner; Christoph J Jensen; Steffen Schneider; Peter Ong; Eva-Maria Kispert; Kai Nassenstein; Thomas Schlosser; Georg V Sabin; Udo Sechtem; Heiko Mahrholdt
Journal:  J Am Coll Cardiol       Date:  2010-06-25       Impact factor: 24.094

4.  Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance.

Authors:  A Selcuk Adabag; Barry J Maron; Evan Appelbaum; Caitlin J Harrigan; Jacqueline L Buros; C Michael Gibson; John R Lesser; Constance A Hanna; James E Udelson; Warren J Manning; Martin S Maron
Journal:  J Am Coll Cardiol       Date:  2008-04-08       Impact factor: 24.094

5.  Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy.

Authors:  Raymond H Chan; Barry J Maron; Iacopo Olivotto; Michael J Pencina; Gabriele Egidy Assenza; Tammy Haas; John R Lesser; Christiane Gruner; Andrew M Crean; Harry Rakowski; James E Udelson; Ethan Rowin; Massimo Lombardi; Franco Cecchi; Benedetta Tomberli; Paolo Spirito; Francesco Formisano; Elena Biagini; Claudio Rapezzi; Carlo Nicola De Cecco; Camillo Autore; E Francis Cook; Susie N Hong; C Michael Gibson; Warren J Manning; Evan Appelbaum; Martin S Maron
Journal:  Circulation       Date:  2014-08-05       Impact factor: 29.690

6.  T1 Mapping in Discrimination of Hypertrophic Phenotypes: Hypertensive Heart Disease and Hypertrophic Cardiomyopathy: Findings From the International T1 Multicenter Cardiovascular Magnetic Resonance Study.

Authors:  Rocio Hinojar; Niharika Varma; Nick Child; Benjamin Goodman; Andrew Jabbour; Chung-Yao Yu; Rolf Gebker; Adelina Doltra; Sebastian Kelle; Sitara Khan; Toby Rogers; Eduardo Arroyo Ucar; Ciara Cummins; Gerald Carr-White; Eike Nagel; Valentina O Puntmann
Journal:  Circ Cardiovasc Imaging       Date:  2015-12       Impact factor: 7.792

7.  Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping.

Authors:  Leah Iles; Heinz Pfluger; Arintaya Phrommintikul; Joshi Cherayath; Pelin Aksit; Sandeep N Gupta; David M Kaye; Andrew J Taylor
Journal:  J Am Coll Cardiol       Date:  2008-11-04       Impact factor: 24.094

8.  Native T1 mapping in differentiation of normal myocardium from diffuse disease in hypertrophic and dilated cardiomyopathy.

Authors:  Valentina O Puntmann; Tobias Voigt; Zhong Chen; Manuel Mayr; Rashed Karim; Kawal Rhode; Ana Pastor; Gerald Carr-White; Reza Razavi; Tobias Schaeffter; Eike Nagel
Journal:  JACC Cardiovasc Imaging       Date:  2013-03-14

9.  Shortened Modified Look-Locker Inversion recovery (ShMOLLI) for clinical myocardial T1-mapping at 1.5 and 3 T within a 9 heartbeat breathhold.

Authors:  Stefan K Piechnik; Vanessa M Ferreira; Erica Dall'Armellina; Lowri E Cochlin; Andreas Greiser; Stefan Neubauer; Matthew D Robson
Journal:  J Cardiovasc Magn Reson       Date:  2010-11-19       Impact factor: 5.364

10.  T1 mapping and survival in systemic light-chain amyloidosis.

Authors:  Sanjay M Banypersad; Marianna Fontana; Viviana Maestrini; Daniel M Sado; Gabriella Captur; Aviva Petrie; Stefan K Piechnik; Carol J Whelan; Anna S Herrey; Julian D Gillmore; Helen J Lachmann; Ashutosh D Wechalekar; Philip N Hawkins; James C Moon
Journal:  Eur Heart J       Date:  2014-11-16       Impact factor: 29.983

View more
  15 in total

1.  Myocardial native-T1 times are elevated as a function of hypertrophy, HbA1c, and heart rate in diabetic adults without diffuse fibrosis.

Authors:  Bonnie Lam; Tori A Stromp; Zhengxiong Hui; Moriel Vandsburger
Journal:  Magn Reson Imaging       Date:  2019-05-21       Impact factor: 2.546

2.  Automated Myocardial T2 and Extracellular Volume Quantification in Cardiac MRI Using Transfer Learning-based Myocardium Segmentation.

Authors:  Yanjie Zhu; Ahmed S Fahmy; Chong Duan; Shiro Nakamori; Reza Nezafat
Journal:  Radiol Artif Intell       Date:  2020-01-29

Review 3.  Clinical application of CMR in cardiomyopathies: evolving concepts and techniques : A position paper of myocardial and pericardial diseases and cardiac magnetic resonance working groups of Italian society of cardiology.

Authors:  Marco Merlo; Giulia Gagno; Anna Baritussio; Barbara Bauce; Elena Biagini; Marco Canepa; Alberto Cipriani; Silvia Castelletti; Santo Dellegrottaglie; Andrea Igoren Guaricci; Massimo Imazio; Giuseppe Limongelli; Maria Beatrice Musumeci; Vanda Parisi; Silvia Pica; Gianluca Pontone; Giancarlo Todiere; Camilla Torlasco; Cristina Basso; Gianfranco Sinagra; Pasquale Perrone Filardi; Ciro Indolfi; Camillo Autore; Andrea Barison
Journal:  Heart Fail Rev       Date:  2022-05-10       Impact factor: 4.654

4.  Image resampling and discretization effect on the estimate of myocardial radiomic features from T1 and T2 mapping in hypertrophic cardiomyopathy.

Authors:  Daniela Marfisi; Carlo Tessa; Chiara Marzi; Jacopo Del Meglio; Stefania Linsalata; Rita Borgheresi; Alessio Lilli; Riccardo Lazzarini; Luca Salvatori; Claudio Vignali; Andrea Barucci; Mario Mascalchi; Giancarlo Casolo; Stefano Diciotti; Antonio Claudio Traino; Marco Giannelli
Journal:  Sci Rep       Date:  2022-06-17       Impact factor: 4.996

5.  Radiomic Analysis of Myocardial Native T1 Imaging Discriminates Between Hypertensive Heart Disease and Hypertrophic Cardiomyopathy.

Authors:  Ulf Neisius; Hossam El-Rewaidy; Shiro Nakamori; Jennifer Rodriguez; Warren J Manning; Reza Nezafat
Journal:  JACC Cardiovasc Imaging       Date:  2019-01-16

6.  Role of T1 Mapping in Inherited Cardiomyopathies.

Authors:  Peter P Swoboda; Adam K McDiarmid; Stephen P Page; John P Greenwood; Sven Plein
Journal:  Eur Cardiol       Date:  2016

7.  Apical Hypertrophic Cardiomyopathy: The Variant Less Known.

Authors:  Rebecca K Hughes; Kristopher D Knott; James Malcolmson; João B Augusto; Saidi A Mohiddin; Peter Kellman; James C Moon; Gabriella Captur
Journal:  J Am Heart Assoc       Date:  2020-02-28       Impact factor: 5.501

8.  Characterization of interstitial diffuse fibrosis patterns using texture analysis of myocardial native T1 mapping.

Authors:  Hossam El-Rewaidy; Ulf Neisius; Shiro Nakamori; Long Ngo; Jennifer Rodriguez; Warren J Manning; Reza Nezafat
Journal:  PLoS One       Date:  2020-06-01       Impact factor: 3.240

Review 9.  Arrhythmic risk stratification by cardiac magnetic resonance tissue characterization: disclosing the arrhythmic substrate within the heart muscle.

Authors:  Aldostefano Porcari; Antonio De Luca; Chrysanthos Grigoratos; Federico Biondi; Giorgio Faganello; Giancarlo Vitrella; Gaetano Nucifora; Giovanni Donato Aquaro; Marco Merlo; Gianfranco Sinagra
Journal:  Heart Fail Rev       Date:  2022-01       Impact factor: 4.214

10.  Cardiac MR Imaging of Hypertrophic Cardiomyopathy: Techniques, Findings, and Clinical Relevance.

Authors:  Yasuo Amano; Mitsunobu Kitamura; Hitoshi Takano; Fumi Yanagisawa; Masaki Tachi; Yasuyuki Suzuki; Shinichiro Kumita; Morimasa Takayama
Journal:  Magn Reson Med Sci       Date:  2018-01-18       Impact factor: 2.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.